Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rosell, R.
Right arrow Articles by Balaña, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosell, R.
Right arrow Articles by Balaña, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S25-S28, 1999
© 1999 European Society for Medical Oncology

Reviews

Ifosfamide in non-small-cell lung cancer

R. Rosell, C. Martin and C. Balaña

Medical Oncology Service, University Hospital Germans Trias i Pujol Badalona, Barcelona, Spain

Correspondence to:R. Rosell, MD, PhD, Medical Oncology Service, University Hospital Germans Trias i Crtra Canyet s/n., 08916 Badalona, Barcelona, Spain, E-mail: rrosell{at}ns.hugtip.scs.es

Ifosfamide has been used in combination with several drugs including cisplatin, giving rise to multiple doublets and triplets including the ifosfamide–cisplatin–mitomycin regimen (Cullen's MIC regimen) that has been commonly used in Europe. However, new combinations are challenging the activity of the old chemotherapy regimens, especially in terms of objective response rate and time to progressive disease, as has been shown in several phase III randomized trials.Among these new combinations, ifosfamide-vinorelbine and ifosfamide–gemcitabine–cisplatin are especially promising. In this paper, several ifosfamide doublets and triplets are reviewed.

doublets, ifosfamide, non-small-cell lung cancer, triplets


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.